Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09XMX
|
||||
Former ID |
DNCL003356
|
||||
Drug Name |
SaxaDapa FDC
|
||||
Company |
AstraZeneca
|
||||
Target and Pathway | |||||
Target(s) | Dipeptidyl peptidase IV | Target Info | Modulator | [530967], [531182] | |
Sodium/glucose cotransporter 2 | Target Info | Modulator | [530967], [531182] | ||
KEGG Pathway | Protein digestion and absorption | ||||
NetPath Pathway | IL2 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
WikiPathways | NRF2 pathway | ||||
References | |||||
Ref 530967 | Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. | ||||
Ref 531182 | The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12. | ||||
Ref 530967 | Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. | ||||
Ref 531182 | The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.